DMD Noab BioDiscoveries - Shaping Drug Discovery

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Drug Metabolism and Disposition Fast Forward
First published on January 13, 2006; DOI: 10.1124/dmd.105.007740


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
dmd.105.007740v1
34/4/539    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Zhang, D.-W.
Right arrow Articles by Deeley, R. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Zhang, D.-W.
Right arrow Articles by Deeley, R. G.


Received for publication November 8, 2005.
Revised January 5, 2006.
Accepted for publication January 12, 2006.

Mutational analysis of polar amino acid residues within predicted transmembrane helices 10 and 16 of Multidrug Resistance Protein 1 (ABCC1): Effect on substrate specificity

Da-Wei Zhang 1, Kenichi Nunoya 2, Monika Vasa 3, Hong-Mei Gu 3, Susan P.C. Cole 3, Roger G. Deeley 4*

1 UT southwestern medical center at Dallas 2 Department of Xenobiotic Metabolism and Disposition, Minase Research Institute 3 Queen's University 4 Cancer Research Institute, Queen's University

* Address correspondence to: E-mail: deeleyr{at}post.queensu.ca

Abstract

Human Multidrug Resistance Protein1 (MRP1) has a total of 17 transmembrane (TM) helices arranged in three domains, MSD0, MSD1 and MSD2 with a 5+6+6 TM configuration. Photolabeling studies indicate that TMs 10 and 11 in MSD1 and 16 and 17 in MSD2 contribute to the substrate binding pocket of the protein. Previous mutational analyses of charged and polar amino acids in predicted TM helices 11, 16 and 17 support this suggestion. Mutation of Trp553 in TM10 also affects substrate specificity. To extend this analysis, we mutated six additional polar residues within TM10 and the remaining uncharacterized polar residue in TM16, Asn1208. Although mutation of Asn1208 was without effect, two of six mutations in TM10, T550A and T556A modulated the drug resistance profile of MRP1 without affecting transport of leukotriene C4, estradiol-17{beta}-D-glucuronide (E217{beta}G) and glutathione. Mutation T550A increased vincristine resistance but decreased doxorubicin resistance, while mutation T556A decreased resistance to VP-16 and doxorubicin. Although conservative mutation of Tyr568 in TM10 to Phe or Trp had no apparent effect on substrate specificity, substitution with Ala decreased the affinity of MRP1 for E217{beta}G without affecting drug resistance or the transport of other substrates tested. These analyses confirm that several amino acids in TM10 selectively alter the substrate specificity of MRP1 suggesting that they interact directly with certain substrates. The location of these and other functionally important residues in TM helices 11, 16 and 17 is discussed in the context of an energy-minimized model of the membrane spanning domains of MRP1.


Key words: ABC transporters, MRP, multi-drug resistance, site-directed mutagenesis


This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
A. A. K. El-Sheikh, J. J. M. W. van den Heuvel, E. Krieger, F. G. M. Russel, and J. B. Koenderink
Functional Role of Arginine 375 in Transmembrane Helix 6 of Multidrug Resistance Protein 4 (MRP4/ABCC4)
Mol. Pharmacol., October 1, 2008; 74(4): 964 - 971.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2006 by the American Society for Pharmacology and Experimental Therapeutics.